Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00658892 · ClinicalTrials.gov registry record · Phase 1
Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT00658892: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT00658892 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00658892, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: Monoclonal antibodies can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This clinical trial is studying the side effects and best dose of a monoclonal antibody in treating patients with stage IV melanoma.
Interventions
- OTHER laboratory biomarker analysis
- OTHER flow cytometry
- OTHER immunologic technique
- BIOLOGICAL B7-DC cross-linking antibody rHIgM12B7
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2008-04-08 |
| Est. Completion | 2012-05-22 |
| Phase | Phase 1 |
What the finished NCT00658892 record still lists
NCT00658892 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00658892 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00658892 about?
NCT00658892 is a clinical study titled "Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma". RATIONALE: Monoclonal antibodies can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. PURPOSE: This clinical trial is studying the side effects and best dose of a mon...
What is the current status of trial NCT00658892?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2008-04-08. Estimated completion is 2012-05-22.
What interventions are being tested in trial NCT00658892?
The interventions under investigation include: laboratory biomarker analysis (OTHER), flow cytometry (OTHER), immunologic technique (OTHER), B7-DC cross-linking antibody rHIgM12B7 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00658892?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00658892's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI